- Home
- LILA vs RCUS Comparison
LILA vs RCUS Comparison
Compare LILA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILA
- RCUS
- Stock Information
- Founded
- LILA 2017
- RCUS 2015
- Country
- LILA Bermuda
- RCUS United States
- Employees
- LILA N/A
- RCUS N/A
- Industry
- LILA Cable & Other Pay Television Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- LILA Telecommunications
- RCUS Health Care
- Exchange
- LILA Nasdaq
- RCUS Nasdaq
- Market Cap
- LILA 1.3B
- RCUS 1.4B
- IPO Year
- LILA N/A
- RCUS 2018
- Fundamental
- Price
- LILA $6.89
- RCUS $13.67
- Analyst Decision
- LILA Buy
- RCUS Buy
- Analyst Count
- LILA 2
- RCUS 12
- Target Price
- LILA $8.65
- RCUS $34.50
- AVG Volume (30 Days)
- LILA 315.1K
- RCUS 583.4K
- Earning Date
- LILA 02-20-2025
- RCUS 02-19-2025
- Dividend Yield
- LILA N/A
- RCUS N/A
- EPS Growth
- LILA N/A
- RCUS N/A
- EPS
- LILA N/A
- RCUS N/A
- Revenue
- LILA $4,470,200,000.00
- RCUS $263,000,000.00
- Revenue This Year
- LILA $1.17
- RCUS $127.65
- Revenue Next Year
- LILA $3.18
- RCUS N/A
- P/E Ratio
- LILA N/A
- RCUS N/A
- Revenue Growth
- LILA N/A
- RCUS 119.17
- 52 Week Low
- LILA $5.90
- RCUS $13.51
- 52 Week High
- LILA $10.82
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- LILA 56.06
- RCUS 36.52
- Support Level
- LILA $6.17
- RCUS $13.81
- Resistance Level
- LILA $7.06
- RCUS $14.45
- Average True Range (ATR)
- LILA 0.20
- RCUS 0.54
- MACD
- LILA 0.09
- RCUS -0.06
- Stochastic Oscillator
- LILA 80.90
- RCUS 18.05
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico, and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.